Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


26.10.2026

3 Ann Hematol
1 Blood
2 BMC Cancer
1 Bone Marrow Transplant
2 Br J Cancer
2 Int J Hematol
1 J Biol Chem
1 J Natl Cancer Inst
3 Leuk Lymphoma
2 Leuk Res
2 Leukemia


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Hematol

  1. ARVIDSSON KVISSBERG M, Nilsson C, Landberg N, Osterroos A, et al
    Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
    Ann Hematol. 2026;105:479.
    PubMed         Abstract available

  2. LI M, Zhang S, Man X, Wen H, et al
    Addition of thiotepa to total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma: a propensity score-matched retrospective study.
    Ann Hematol. 2026;105:467.
    PubMed         Abstract available

  3. GALLARDO CA, Hew YY, Jen WY, Hemalatha S, et al
    A rare case of acute basophilic leukemia transformed from high risk myelodysplastic syndrome.
    Ann Hematol. 2026;105:465.
    PubMed         Abstract available


    Blood

  4. WEEKS LD, Neuberg D, Limerick EM, Hsieh MM, et al
    Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease.
    Blood. 2026;148:2099-2109.
    PubMed         Abstract available


    BMC Cancer

  5. MUTHUKUMARAN M, Selvam P, Dhandapani PB, Veeramani N, et al
    ClinNetDx: a novel explainable ai framework for acute lymphoblastic leukemia detection using multi-modal clinical data.
    BMC Cancer. 2026;26:1268.
    PubMed         Abstract available

  6. HUANG G, Cai X, Zhou Y, Liu Y, et al
    Serglycin-ROS axis mediates synergistic lethality of PI3Kgamma inhibition and Azacitidine in TP53-mutated AML.
    BMC Cancer. 2026;26:1251.
    PubMed         Abstract available


    Bone Marrow Transplant

  7. ZHANG X, Feng D, Cao Y, Xu M, et al
    The prognostic impact of CEBPA mutation in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2026 Oct 16. doi: 10.1038/s41409-026-03068.
    PubMed         Abstract available


    Br J Cancer

  8. JIMENEZ-CAMACHO KE, Vargas-Robles H, Adomako J, Sanchez-Argaez AB, et al
    HDAC6 is a biomarker of leukaemic dissemination and relapse in B-ALL.
    Br J Cancer. 2026;135:1470-1482.
    PubMed         Abstract available

  9. BANSAL S, Gupta AK, Meena JP, Sehgal T, et al
    Romiplostim for chemotherapy induced thrombocytopenia in pediatric cancers.
    Br J Cancer. 2026;135:1417-1423.
    PubMed         Abstract available


    Int J Hematol

  10. TEROL MJ, Serrano A, Ferrer-Lores B, Bosch F, et al
    TP53 mutations and IGHV in naive chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative network.
    Int J Hematol. 2026 Oct 20. doi: 10.1007/s12185-026-04285.
    PubMed         Abstract available

  11. SHARIF MI, Perusini AM, Sibai H, Kim DDH, et al
    Current perspectives on high-risk genomic profiles in chronic myeloid leukemia: from bench to clinical practice.
    Int J Hematol. 2026 Oct 21. doi: 10.1007/s12185-026-04301.
    PubMed         Abstract available


    J Biol Chem

  12. SHENG C, Xu Z, Hu C, Wu S, et al
    Biomimetic Sodium Transporters Induce Intracellular Sodium Overload to Activate p53-Mediated Apoptosis and Cell Cycle Arrest in Acute Myeloid Leukemia.
    J Biol Chem. 2026 Oct 22:113679. doi: 10.1016/j.jbc.2026.113679.
    PubMed         Abstract available


    J Natl Cancer Inst

  13. COLACE SI, Pommert L, Leger KJ, Rushing T, et al
    Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
    J Natl Cancer Inst. 2026 Oct 19:djag393. doi: 10.1093.
    PubMed         Abstract available


    Leuk Lymphoma

  14. PATEL T, Shah N, Heyman B, Kipps T, et al
    Immunoglobulin kinetics and infection patterns across venetoclax-based regimens in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2026 Oct 20:1-12. doi: 10.1080/10428194.2026.2745238.
    PubMed         Abstract available

  15. GARCIA JS, Desai P, Zeidner JF, Wolach O, et al
    Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.
    Leuk Lymphoma. 2026;67:2282-2294.
    PubMed         Abstract available

  16. VEY N, Salamero O, Bajel A, Montesinos P, et al
    Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
    Leuk Lymphoma. 2026;67:2305-2312.
    PubMed         Abstract available


    Leuk Res

  17. ATALLAH EL, Sadek I, McGovern E, Latremouille-Viau D, et al
    Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia.
    Leuk Res. 2026;171:108345.
    PubMed         Abstract available

  18. CIFTCILER R, Haznedaroglu IC
    From standardization to precision medicine: Evolution of European Leukemianet recommendations in Philadelphia-negative myeloproliferative neoplasms.
    Leuk Res. 2026;170:108303.
    PubMed         Abstract available


    Leukemia

  19. FIORICA G, Wehmeyer G, Yee CI, Segovia D, et al
    Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis.
    Leukemia. 2026 Oct 22. doi: 10.1038/s41375-026-03178.
    PubMed        

  20. VISENTIN A, Gaffo E, Furstenau M, Rogers KA, et al
    Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
    Leukemia. 2026 Oct 16. doi: 10.1038/s41375-026-03167.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum